MABA for Autism Spectrum Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Autism Spectrum Disorder+2 More
EIBI - Behavioral
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying a less intensive form of behavior intervention for autism spectrum disorder (ASD) to see if it is effective and causes less stress for parents.

Eligible Conditions
  • Autism Spectrum Disorder
  • Autism Spectrum Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Autism Spectrum Disorder

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Baseline, Week4, Week 12, Week24, Week48, Week 90, Age 5

Week 12
Change in ASD symptoms using the Ohio Autism Clinical Impressions Scale (OACIS)
Week 90
Body Weight Changes

Trial Safety

Safety Progress

1 of 3

Other trials for Autism Spectrum Disorder

Trial Design

2 Treatment Groups

MABA
1 of 2
EIBI
1 of 2
Active Control

60 Total Participants · 2 Treatment Groups

Primary Treatment: MABA · No Placebo Group · N/A

MABA
Behavioral
ActiveComparator Group · 1 Intervention: MABA · Intervention Types: Behavioral
EIBI
Behavioral
ActiveComparator Group · 1 Intervention: EIBI · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, week4, week 12, week24, week48, week 90, age 5

Who is running the clinical trial?

May InstituteOTHER
2 Previous Clinical Trials
192 Total Patients Enrolled
2 Trials studying Autism Spectrum Disorder
192 Patients Enrolled for Autism Spectrum Disorder
University of MichiganOTHER
1,615 Previous Clinical Trials
6,330,746 Total Patients Enrolled
6 Trials studying Autism Spectrum Disorder
1,241 Patients Enrolled for Autism Spectrum Disorder
University of VirginiaOTHER
679 Previous Clinical Trials
1,425,724 Total Patients Enrolled
1 Trials studying Autism Spectrum Disorder
6,604 Patients Enrolled for Autism Spectrum Disorder
University of RochesterLead Sponsor
787 Previous Clinical Trials
500,577 Total Patients Enrolled
11 Trials studying Autism Spectrum Disorder
9,533 Patients Enrolled for Autism Spectrum Disorder
The Cleveland ClinicOTHER
940 Previous Clinical Trials
1,407,282 Total Patients Enrolled
4 Trials studying Autism Spectrum Disorder
662 Patients Enrolled for Autism Spectrum Disorder
Vanderbilt University Medical CenterOTHER
768 Previous Clinical Trials
592,054 Total Patients Enrolled
13 Trials studying Autism Spectrum Disorder
2,411 Patients Enrolled for Autism Spectrum Disorder
Nationwide Children's HospitalOTHER
305 Previous Clinical Trials
5,209,982 Total Patients Enrolled
10 Trials studying Autism Spectrum Disorder
9,185 Patients Enrolled for Autism Spectrum Disorder

Eligibility Criteria

Age < 18 · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Virginia100.0%
How old are they?
< 18100.0%
What site did they apply to?
May Institute100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%